

10/18/00
JC955 U.S. PTO

10/20/00

A


Attorney Docket P1748R1
PATENT

JC926 U.S. PTO
09/692504
10/18/00

CERTIFICATION UNDER 37 CFR 1.10

EL 599 583 405 US: Express Mail Number **October 18, 2000:** Date of Deposit

I hereby certify that this Non-provisional Application Transmittal and the documents referred to as enclosed therein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231.


Aida Gufam

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BOX PATENT APPLICATION
Assistant Commissioner of Patents
Washington, D.C. 20231

NON-PROVISIONAL APPLICATION TRANSMITTAL UNDER 37 CFR 1.53(b)

Transmitted herewith for filing is a non-provisional patent application:

Inventor(s) (or Application "Identifier"):

**Frederic DeSavage,
Iqbal Grewal
Austin L. Gurney**

Title: **TYPE I CYTOKINE RECEPTOR TCCR**

1. Type of Application

- ☐ This application is for an original, non-provisional application.
- ☒ This is a non-provisional application claiming priority to provisional application no. 60/160,542 , filed October 20, 1999 , the entire disclosure of which is hereby incorporated by reference.
- ☐ This is a ☐ continuation-in-part ☐ continuation ☐ divisional application claiming priority to application Serial Number __, filed __, the entire disclosure of which is hereby incorporated by reference.

**2. Papers Enclosed Which Are Required For Filing Date Under 37 CFR 1.53(b)
(Non-provisional)**

124 pages of specification
4 pages of claims
1 page(s) of abstract
18 sheet(s) of drawings
☐ formal ☒ informal

3. Declaration or Oath

(for new and CIP applications; also for Cont./Div. where inventor(s) are being added)
 X An executed declaration of the inventor(s) [x] is enclosed [] will follow.

(for Cont./Div. where inventorship is the same or inventor(s) being deleted)
 A copy of the executed declaration/oath filed in the prior application is enclosed
(37 CFR 1.63(d)).

(for Cont./Div. where inventor(s) being deleted)
 A signed statement is attached deleting inventor(s) named in the prior
application (see 37 CFR 1.63(d)(2) and 1.33(b)).

4. Assignment

(for new and CIP applications)
 x An Assignment of the invention to GENENTECH, INC. [x] is enclosed with
attached Recordation Form Cover Sheet [] will follow.

(for cont./div.)
 The prior application is assigned of record to Genentech, Inc.

5. Amendments (for continuation and divisional applications)

 Cancel in this application original claims __ of the prior application before calculating the filing
fee. (At least one original independent claim must be retained for filing purposes.)

 A preliminary amendment is enclosed. (Claims added by this amendment have been
properly numbered consecutively beginning with the number next following the highest
numbered original claim in the prior application.)

Relate Back -- 35 U.S.C. 120 or 35 U.S.C. 119

 Amend the specification by inserting before the first line the sentence:

--This is a

 non-provisional application
 continuation
 divisional
 continuation-in-part

of co-pending application(s)

 Serial No. _ filed on __, which application(s) is(are) incorporated herein by reference and to
which application(s) priority is claimed under 35 USC §120. --

 International Application _ filed on __ which designated the U.S., which application(s) is(are)
incorporated herein by reference and to which application(s) priority is claimed under 35
USC §120.--

_____ provisional application No. _ filed _, the entire disclosure of which is hereby incorporated by reference and to which application(s) priority is claimed under 35 USC §119.--.

6. Fee Calculation (37 CFR 1.16)

The fee has been calculated as follows:

CLAIMS FOR FEE CALCULATION					
Number Filed		Number Extra		Rate	Basic Fee 37 CFR 1.16(a)
					\$710.00
Total Claims	34	- 20 =	14	X \$18.00	\$252.00
Independent Claims	8	- 3 =	5	X \$80.00	\$400.00
Multiple dependent claim(s), if any				+ \$270.00	\$0.00
Filing Fee Calculation					\$1,362.00

7. Method of Payment of Fees

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$1,362.00. **A duplicate copy of this transmittal is enclosed.**

8. Authorization to Charge Additional Fees

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. **A duplicate copy of this sheet is enclosed.**

9. Additional Papers Enclosed

- ☐ Information Disclosure Statement (37 CFR §1.98) w/ PTO-1449 and citations
- ☒ Submission of "Sequence Listing", computer readable copy, certificate re: sequence listing, and/or amendment pertaining thereto for biological invention containing nucleotide and/or amino acid sequence.
- ☐ A new Power of Attorney or authorization of agent.
- ☐ Other:

10. Maintenance of Copendency of Prior Application (for continuation and divisional applications)

[This item must be completed and the necessary papers filed in the prior application if the period set in the prior application has run]

- _____ A petition, fee and/or response has been filed to extend the term in the pending prior application until
- _____ A copy of the petition for extension of time in the **prior** application is attached.


11. Correspondence Address:

X Address all future communications to:

GENENTECH, INC.
Attn: Atulya R. Agarwal, Ph.D.
1 DNA Way
South San Francisco, CA 94080-4990
(650) 225-4463


Respectfully submitted,
GENENTECH, INC.

Date: October 18, 2000

By: 
Atulya R. Agarwal, Ph.D.
Reg. No. 40,887

1 DNA Way
So. San Francisco, CA 94080-4990
Phone: (650) 225-4463
Fax: (650) 952-9881

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<p>In re Application of Frederic DeSavage et al. Serial No.: To Be Assigned Filed: October 18, 2000 For: TYPE I CYTOKINE RECEPTOR TCCR</p>	<p>Group Art Unit: NOT KNOWN Examiner: NOT KNOWN</p> <hr/> <p>CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231, on October 18, 2000  Aida Guim</p>
----------------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CERTIFICATE RE: SEQUENCE LISTING

BOX SEQUENCES


Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

I hereby state that the Sequence Listing submitted herewith is submitted in paper copy and a computer-readable diskette, and that the information recorded in computer readable form is identical to the written sequence listing. I further state that this submission includes no new matter.

Respectfully submitted,
GENENTECH, INC.

Date: October 18, 2000

By: 
Atulya R. Agarwal, Ph.D.
Reg. No. 40,887

1 DNA Way
So. San Francisco, CA 94080-4990
Phone: (650) 225-4463
Fax: (650) 952-9881